person · Reporting owner

Mikan George Lawrence III

Disclosed activity across 4 companies

Tapewire entity: 13004
SEC CIK: 0001381037

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
AUTONATION, INC.AN · Entity 3730	Director	January 02, 2026	January 06, 2026
ELLINGTON INCOME OPPORTUNITIES FUNDEIOM · Entity 112529	Trustee	October 18, 2018	November 01, 2018
UNITEDHEALTH GROUP INCUNH · Entity 2809	EVP UHG & CEO, Optum	June 05, 2011	June 07, 2011

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AUTONATION, INC.

Report date January 02, 2026 · Filed January 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.01 per shareSEC Table I · non-derivative	Direct	22,170	Reported balance After 2026-01-02 transaction · row 1 1 source row Row 1 · 2026-01-02 · Grant · Acquired 1,210 · Balance 22,170 F1: 2026 grant of 1,210 vested restricted stock units (the "RSUs") pursuant to the AutoNation, Inc. 2024 Non-Employee Director Equity Plan (the "2024 Director Plan"). The RSUs will settle in shares of common stock, par value $0.01 per share, of AutoNation, Inc. (the "Company") in accordance with the terms of the award, including any deferral election made by the reporting person, and the 2024 Director Plan. Settlement of the RSUs will be accelerated in certain circumstances as provided in the terms of the award and the 2024 Director Plan, including in the event the reporting person ceases to serve as a non-employee director of the Company.
Common Stock, par value $0.01 per shareSEC Table I · non-derivative	IndirectBy Trust	14,259	Reported balance Holding disclosure · report date 2026-01-02 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 14,259

Filing footnotes · ownership attribution and instrument terms

F1: 2026 grant of 1,210 vested restricted stock units (the "RSUs") pursuant to the AutoNation, Inc. 2024 Non-Employee Director Equity Plan (the "2024 Director Plan"). The RSUs will settle in shares of common stock, par value $0.01 per share, of AutoNation, Inc. (the "Company") in accordance with the terms of the award, including any deferral election made by the reporting person, and the 2024 Director Plan. Settlement of the RSUs will be accelerated in certain circumstances as provided in the terms of the award and the 2024 Director Plan, including in the event the reporting person ceases to serve as a non-employee director of the Company.

ELLINGTON INCOME OPPORTUNITIES FUND

Report date October 18, 2018 · Filed November 01, 2018

This filing explicitly reported no securities owned.

UNITEDHEALTH GROUP INC

Report date June 05, 2011 · Filed June 07, 2011

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	209,278.777	Reported balance After 2011-06-05 transaction · row 1 1 source row Row 1 · 2011-06-05 · Tax withholding · Disposed 3,892 · Balance 209,278.777
Common StockSEC Table I · non-derivative	Indirectby 401(k)	142.9422	Reported balance Holding disclosure · report date 2011-06-05 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 142.9422

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

NeueHealth, Inc.

Report date October 02, 2025 · Filed October 06, 2025

Section 16 reporting ended · disclosed 2025-10-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2025-10-02 transaction · row 1 1 source row Row 1 · 2025-10-02 · Disposition to issuer · Disposed 249,453 · Balance 0 F1: On October 2, 2025, NH Holdings 2025, Inc. ("Parent"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and NH Holdings Acquisition 2025, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), dated as of December 23, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). Parent and Merger Sub are indirectly controlled by private investment funds affiliated with New Enterprise Associates, Inc. F2: Pursuant to the Rollover Agreement, dated as of September 17, 2025 (the "Rollover Agreement"), entered into by and among NH Holdings 2025 SPV, L.P. ("Holdings"), NH Holdings 2025, Inc., NH Holdings Acquisition 2025, Inc. and the Reporting Person, the Reporting Person contributed its shares of Issuer common stock, Series A Convertible Perpetual Preferred Stock ("Series A Preferred Stock") and Series B Convertible Perpetual Preferred Stock ("Series B Preferred Stock") to Holdings in exchange for Holdings common units, series A preferred units and series B preferred units on a one for one basis in accordance with the Rollover Agreement, and effective as of the effective time of the Merger (the "Effective Time").
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2025-10-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-10-02 · Disposition to issuer · Disposed 58,876 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F1: On October 2, 2025, NH Holdings 2025, Inc. ("Parent"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and NH Holdings Acquisition 2025, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), dated as of December 23, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). Parent and Merger Sub are indirectly controlled by private investment funds affiliated with New Enterprise Associates, Inc. F5: Each Issuer restricted stock unit ("RSU") outstanding immediately prior to the Effective Time was assumed and adjusted into a restricted stock unit with respect to a number of shares of common stock of Parent equal to the number of shares of Issuer common stock subject to such Issuer RSU and continued to be subject to the same terms and restrictions set forth in the Issuer equity plans and any applicable individual award agreement issued thereunder (including with respect to vesting). F4: The original grant of these restricted stock units vest in equal annual installments beginning on 3/6/23.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2025-10-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-10-02 · Disposition to issuer · Disposed 260,000 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F1: On October 2, 2025, NH Holdings 2025, Inc. ("Parent"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and NH Holdings Acquisition 2025, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), dated as of December 23, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). Parent and Merger Sub are indirectly controlled by private investment funds affiliated with New Enterprise Associates, Inc. F5: Each Issuer restricted stock unit ("RSU") outstanding immediately prior to the Effective Time was assumed and adjusted into a restricted stock unit with respect to a number of shares of common stock of Parent equal to the number of shares of Issuer common stock subject to such Issuer RSU and continued to be subject to the same terms and restrictions set forth in the Issuer equity plans and any applicable individual award agreement issued thereunder (including with respect to vesting). F6: The original grant of these restricted stock units vest in equal annual installments beginning on 3/11/24.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2025-10-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-10-02 · Disposition to issuer · Disposed 580,000 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F1: On October 2, 2025, NH Holdings 2025, Inc. ("Parent"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and NH Holdings Acquisition 2025, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), dated as of December 23, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). Parent and Merger Sub are indirectly controlled by private investment funds affiliated with New Enterprise Associates, Inc. F5: Each Issuer restricted stock unit ("RSU") outstanding immediately prior to the Effective Time was assumed and adjusted into a restricted stock unit with respect to a number of shares of common stock of Parent equal to the number of shares of Issuer common stock subject to such Issuer RSU and continued to be subject to the same terms and restrictions set forth in the Issuer equity plans and any applicable individual award agreement issued thereunder (including with respect to vesting). F7: All of these restricted stock units vest on 10/11/26.

Filing footnotes · ownership attribution and instrument terms

F1: On October 2, 2025, NH Holdings 2025, Inc. ("Parent"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and NH Holdings Acquisition 2025, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), dated as of December 23, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). Parent and Merger Sub are indirectly controlled by private investment funds affiliated with New Enterprise Associates, Inc.

F2: Pursuant to the Rollover Agreement, dated as of September 17, 2025 (the "Rollover Agreement"), entered into by and among NH Holdings 2025 SPV, L.P. ("Holdings"), NH Holdings 2025, Inc., NH Holdings Acquisition 2025, Inc. and the Reporting Person, the Reporting Person contributed its shares of Issuer common stock, Series A Convertible Perpetual Preferred Stock ("Series A Preferred Stock") and Series B Convertible Perpetual Preferred Stock ("Series B Preferred Stock") to Holdings in exchange for Holdings common units, series A preferred units and series B preferred units on a one for one basis in accordance with the Rollover Agreement, and effective as of the effective time of the Merger (the "Effective Time").

F3: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F4: The original grant of these restricted stock units vest in equal annual installments beginning on 3/6/23.

F5: Each Issuer restricted stock unit ("RSU") outstanding immediately prior to the Effective Time was assumed and adjusted into a restricted stock unit with respect to a number of shares of common stock of Parent equal to the number of shares of Issuer common stock subject to such Issuer RSU and continued to be subject to the same terms and restrictions set forth in the Issuer equity plans and any applicable individual award agreement issued thereunder (including with respect to vesting).

F6: The original grant of these restricted stock units vest in equal annual installments beginning on 3/11/24.

F7: All of these restricted stock units vest on 10/11/26.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 02, 2026 Filed Jan 6, 2026 21:25 UTC	AUTONATION, INC. AN · Entity 3730	GrantCommon Stock, par value $0.01 per share	1,210	$0.00	$0.00	Disclosure SEC source: 0000350698-26-000007 · wk-form4_1767734731.xml · nonDerivative · entry 1 Mikan George Lawrence III · CIK 0001381037 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,170 F1 · kind: 2026 grant of 1,210 vested restricted stock units (the "RSUs") pursuant to the AutoNation, Inc. 2024 Non-Employee Director Equity Plan (the "2024 Director Plan"). The RSUs will settle in shares of common stock, par value $0.01 per share, of AutoNation, Inc. (the "Company") in accordance with the terms of the award, including any deferral election made by the reporting person, and the 2024 Director Plan. Settlement of the RSUs will be accelerated in certain circumstances as provided in the terms of the award and the 2024 Director Plan, including in the event the reporting person ceases to serve as a non-employee director of the Company. Read SEC document
October 02, 2025 Filed Oct 6, 2025 22:20 UTC	NeueHealth, Inc. NEUE · Entity 74308	Disposition to issuerRestricted Stock Units · Derivative	580,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-25-044376 · wk-form4_1759789249.xml · derivative · entry 4 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 580,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F1 · kind: On October 2, 2025, NH Holdings 2025, Inc. ("Parent"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and NH Holdings Acquisition 2025, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), dated as of December 23, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). Parent and Merger Sub are indirectly controlled by private investment funds affiliated with New Enterprise Associates, Inc. F5 · price: Each Issuer restricted stock unit ("RSU") outstanding immediately prior to the Effective Time was assumed and adjusted into a restricted stock unit with respect to a number of shares of common stock of Parent equal to the number of shares of Issuer common stock subject to such Issuer RSU and continued to be subject to the same terms and restrictions set forth in the Issuer equity plans and any applicable individual award agreement issued thereunder (including with respect to vesting). F7 · derivative.exercise_date: All of these restricted stock units vest on 10/11/26. F7 · derivative.expiration_date: All of these restricted stock units vest on 10/11/26. Read SEC document
October 02, 2025 Filed Oct 6, 2025 22:20 UTC	NeueHealth, Inc. NEUE · Entity 74308	Disposition to issuerRestricted Stock Units · Derivative	260,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-25-044376 · wk-form4_1759789249.xml · derivative · entry 3 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 260,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F1 · kind: On October 2, 2025, NH Holdings 2025, Inc. ("Parent"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and NH Holdings Acquisition 2025, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), dated as of December 23, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). Parent and Merger Sub are indirectly controlled by private investment funds affiliated with New Enterprise Associates, Inc. F5 · price: Each Issuer restricted stock unit ("RSU") outstanding immediately prior to the Effective Time was assumed and adjusted into a restricted stock unit with respect to a number of shares of common stock of Parent equal to the number of shares of Issuer common stock subject to such Issuer RSU and continued to be subject to the same terms and restrictions set forth in the Issuer equity plans and any applicable individual award agreement issued thereunder (including with respect to vesting). F6 · derivative.exercise_date: The original grant of these restricted stock units vest in equal annual installments beginning on 3/11/24. F6 · derivative.expiration_date: The original grant of these restricted stock units vest in equal annual installments beginning on 3/11/24. Read SEC document
October 02, 2025 Filed Oct 6, 2025 22:20 UTC	NeueHealth, Inc. NEUE · Entity 74308	Disposition to issuerRestricted Stock Units · Derivative	58,876	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-25-044376 · wk-form4_1759789249.xml · derivative · entry 2 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 58,876 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F1 · kind: On October 2, 2025, NH Holdings 2025, Inc. ("Parent"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and NH Holdings Acquisition 2025, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), dated as of December 23, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). Parent and Merger Sub are indirectly controlled by private investment funds affiliated with New Enterprise Associates, Inc. F5 · price: Each Issuer restricted stock unit ("RSU") outstanding immediately prior to the Effective Time was assumed and adjusted into a restricted stock unit with respect to a number of shares of common stock of Parent equal to the number of shares of Issuer common stock subject to such Issuer RSU and continued to be subject to the same terms and restrictions set forth in the Issuer equity plans and any applicable individual award agreement issued thereunder (including with respect to vesting). F4 · derivative.exercise_date: The original grant of these restricted stock units vest in equal annual installments beginning on 3/6/23. F4 · derivative.expiration_date: The original grant of these restricted stock units vest in equal annual installments beginning on 3/6/23. Read SEC document
October 02, 2025 Filed Oct 6, 2025 22:20 UTC	NeueHealth, Inc. NEUE · Entity 74308	Disposition to issuerCommon Stock	249,453	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-25-044376 · wk-form4_1759789249.xml · nonDerivative · entry 1 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: On October 2, 2025, NH Holdings 2025, Inc. ("Parent"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and NH Holdings Acquisition 2025, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), dated as of December 23, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). Parent and Merger Sub are indirectly controlled by private investment funds affiliated with New Enterprise Associates, Inc. F2 · price: Pursuant to the Rollover Agreement, dated as of September 17, 2025 (the "Rollover Agreement"), entered into by and among NH Holdings 2025 SPV, L.P. ("Holdings"), NH Holdings 2025, Inc., NH Holdings Acquisition 2025, Inc. and the Reporting Person, the Reporting Person contributed its shares of Issuer common stock, Series A Convertible Perpetual Preferred Stock ("Series A Preferred Stock") and Series B Convertible Perpetual Preferred Stock ("Series B Preferred Stock") to Holdings in exchange for Holdings common units, series A preferred units and series B preferred units on a one for one basis in accordance with the Rollover Agreement, and effective as of the effective time of the Merger (the "Effective Time"). Read SEC document
March 14, 2025 Filed Mar 18, 2025 00:36 UTC	NeueHealth, Inc. NEUE · Entity 74308	SaleCommon Stock	12,440	$6.13	$76,257.20	Disclosure SEC source: 0001628280-25-013316 · wk-form4_1742258167.xml · nonDerivative · entry 2 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 249,454 F1 · shares: These shares were sold by the reporting person to cover tax withholding obligations upon the vesting of restricted stock units and were not discretionary transactions by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.90 to $6.99 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
March 13, 2025 Filed Mar 18, 2025 00:36 UTC	NeueHealth, Inc. NEUE · Entity 74308	SaleCommon Stock	35,896	$6.74	$241,939.04	Disclosure SEC source: 0001628280-25-013316 · wk-form4_1742258167.xml · nonDerivative · entry 1 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 261,894 F1 · shares: These shares were sold by the reporting person to cover tax withholding obligations upon the vesting of restricted stock units and were not discretionary transactions by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.63 to $6.85 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
March 12, 2025 Filed Mar 14, 2025 01:45 UTC	NeueHealth, Inc. NEUE · Entity 74308	SaleCommon Stock	13,180	$6.93	$91,337.40	Disclosure SEC source: 0001628280-25-012706 · wk-form4_1741916710.xml · nonDerivative · entry 3 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 297,790 F1 · shares: These shares were sold by the reporting person to cover tax withholding obligations upon the vesting of restricted stock units and were not discretionary transactions by the reporting person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.71 to $6.98 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
March 11, 2025 Filed Mar 14, 2025 01:45 UTC	NeueHealth, Inc. NEUE · Entity 74308	Exercise / conversionRestricted Stock Units · Derivative	130,000	$0.00	$0.00	Disclosure SEC source: 0001628280-25-012706 · wk-form4_1741916710.xml · derivative · entry 4 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 260,000 Underlying: Common Stock · 130,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: These restricted stock units vest in three equal annual installments beginning on March 11, 2025. F5 · derivative.expiration_date: These restricted stock units vest in three equal annual installments beginning on March 11, 2025. Read SEC document
March 11, 2025 Filed Mar 14, 2025 01:45 UTC	NeueHealth, Inc. NEUE · Entity 74308	Exercise / conversionCommon Stock	130,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-25-012706 · wk-form4_1741916710.xml · nonDerivative · entry 2 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 310,970 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
March 11, 2025 Filed Mar 14, 2025 01:45 UTC	NeueHealth, Inc. NEUE · Entity 74308	SaleCommon Stock	3,747	$6.85	$25,666.95	Disclosure SEC source: 0001628280-25-012706 · wk-form4_1741916710.xml · nonDerivative · entry 1 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,970 F1 · shares: These shares were sold by the reporting person to cover tax withholding obligations upon the vesting of restricted stock units and were not discretionary transactions by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.83 to $6.90 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
March 10, 2025 Filed Mar 12, 2025 01:49 UTC	NeueHealth, Inc. NEUE · Entity 74308	SaleCommon Stock	1,604	$7.06	$11,324.24	Disclosure SEC source: 0001628280-25-012195 · wk-form4_1741744190.xml · nonDerivative · entry 3 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,717 F1 · shares: These shares were sold by the reporting person to cover tax withholding obligations upon the vesting of restricted stock units and were not discretionary transactions by the reporting person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.90 and $7.18 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
March 07, 2025 Filed Mar 12, 2025 01:49 UTC	NeueHealth, Inc. NEUE · Entity 74308	Exercise / conversionRestricted Stock Units · Derivative	7,565	$0.00	$0.00	Disclosure SEC source: 0001628280-25-012195 · wk-form4_1741744190.xml · derivative · entry 4 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,565 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: These restricted stock units vested in three equal annual installments beginning on March 7, 2023. F5 · derivative.expiration_date: These restricted stock units vested in three equal annual installments beginning on March 7, 2023. Read SEC document
March 07, 2025 Filed Mar 12, 2025 01:49 UTC	NeueHealth, Inc. NEUE · Entity 74308	Exercise / conversionCommon Stock	7,565	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-25-012195 · wk-form4_1741744190.xml · nonDerivative · entry 2 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,321 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
March 07, 2025 Filed Mar 12, 2025 01:49 UTC	NeueHealth, Inc. NEUE · Entity 74308	SaleCommon Stock	26,660	$7.19	$191,685.40	Disclosure SEC source: 0001628280-25-012195 · wk-form4_1741744190.xml · nonDerivative · entry 1 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,756 F1 · shares: These shares were sold by the reporting person to cover tax withholding obligations upon the vesting of restricted stock units and were not discretionary transactions by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.10 and $7.25 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
March 06, 2025 Filed Mar 11, 2025 00:34 UTC	NeueHealth, Inc. NEUE · Entity 74308	Exercise / conversionRestricted Stock Units · Derivative	58,877	$0.00	$0.00	Disclosure SEC source: 0001628280-25-011803 · wk-form4_1741653254.xml · derivative · entry 2 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,876 Underlying: Common Stock · 58,877 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: These restricted stock units vest in three equal annual installments beginning on March 6, 2024. F2 · derivative.expiration_date: These restricted stock units vest in three equal annual installments beginning on March 6, 2024. Read SEC document
March 06, 2025 Filed Mar 11, 2025 00:34 UTC	NeueHealth, Inc. NEUE · Entity 74308	Exercise / conversionCommon Stock	58,877	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-25-011803 · wk-form4_1741653254.xml · nonDerivative · entry 1 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,416 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
January 06, 2025 Filed Jan 9, 2025 01:53 UTC	NeueHealth, Inc. NEUE · Entity 74308	SaleCommon Stock	31,798	$7.33	$233,079.34	Disclosure SEC source: 0001628280-25-001006 · wk-form4_1736387614.xml · nonDerivative · entry 1 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,539 F1 · shares: These shares were sold by the reporting person to cover tax withholding obligations upon the vesting of restricted stock units and were not discretionary transactions by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.18 to $7.50 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
January 03, 2025 Filed Jan 8, 2025 02:57 UTC	NeueHealth, Inc. NEUE · Entity 74308	Exercise / conversionRestricted Stock Units · Derivative	95,308	$0.00	$0.00	Disclosure SEC source: 0001628280-25-000816 · wk-form4_1736305022.xml · derivative · entry 2 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 95,308 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: All restricted stock units vested on the second anniversary of the grant date. F2 · derivative.expiration_date: All restricted stock units vested on the second anniversary of the grant date. Read SEC document
January 03, 2025 Filed Jan 8, 2025 02:57 UTC	NeueHealth, Inc. NEUE · Entity 74308	Exercise / conversionCommon Stock	95,308	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-25-000816 · wk-form4_1736305022.xml · nonDerivative · entry 1 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,337 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
January 02, 2025 Filed Jan 3, 2025 21:42 UTC	AUTONATION, INC. AN · Entity 3730	GrantCommon Stock, par value $0.01 per share	1,497	$0.00	$0.00	Disclosure SEC source: 0000350698-25-000019 · wk-form4_1735940558.xml · nonDerivative · entry 1 Mikan George Lawrence III · CIK 0001381037 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,960 F1 · kind: 2025 grant of 1,497 vested restricted stock units (the "RSUs") pursuant to the AutoNation, Inc. 2024 Non-Employee Director Equity Plan (the "2024 Director Plan"). The RSUs will settle in shares of common stock, par value $0.01 per share, of AutoNation, Inc. (the "Company") in accordance with the terms of the award, including any deferral election made by the reporting person, and the 2024 Director Plan. Settlement of the RSUs will be accelerated in certain circumstances as provided in the terms of the award and the 2024 Director Plan, including in the event the reporting person ceases to serve as a non-employee director of the Company. Read SEC document
December 17, 2024 Filed Dec 19, 2024 02:15 UTC	NeueHealth, Inc. NEUE · Entity 74308	SaleCommon Stock	16,803	$4.18	$70,236.54	Disclosure SEC source: 0001628280-24-051940 · wk-form4_1734574495.xml · nonDerivative · entry 2 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,029 F2 · shares: These shares were sold by the reporting person to cover tax withholding obligations upon the vesting of restricted stock units and were not discretionary transactions by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.99 to $4.60 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
December 14, 2024 Filed Dec 19, 2024 02:15 UTC	NeueHealth, Inc. NEUE · Entity 74308	Exercise / conversionRestricted Stock Units · Derivative	35,000	$0.00	$0.00	Disclosure SEC source: 0001628280-24-051940 · wk-form4_1734574495.xml · derivative · entry 3 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: 60% of the restricted stock units awarded vested on the 2nd anniversary of the grant date and 40% vested on the 3rd anniversary of the grant date. F4 · derivative.expiration_date: 60% of the restricted stock units awarded vested on the 2nd anniversary of the grant date and 40% vested on the 3rd anniversary of the grant date. Read SEC document
December 14, 2024 Filed Dec 19, 2024 02:15 UTC	NeueHealth, Inc. NEUE · Entity 74308	Exercise / conversionCommon Stock	35,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-24-051940 · wk-form4_1734574495.xml · nonDerivative · entry 1 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,832 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
May 02, 2024 Filed May 6, 2024 22:04 UTC	NeueHealth, Inc. NEUE · Entity 74308	GrantRestricted Stock Units · Derivative	390,000	$0.00	$0.00	Disclosure SEC source: 0001628280-24-020775 · wk-form4_1715033080.xml · derivative · entry 2 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 390,000 Underlying: Common Stock · 390,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · shares: This grant was approved on March 11, 2024 by the Issuer's Compensation and Human Capital Committee as part of the Issuer's annual equity grants, subject to shareholder approval of an amendment to the Issuer's Amended and Restated 2021 Omnibus Incentive Plan, which approval was obtained on May 2, 2024. F5 · derivative.exercise_date: These restricted stock units vest in three equal annual installments beginning on March 11, 2025. F5 · derivative.expiration_date: These restricted stock units vest in three equal annual installments beginning on March 11, 2025. Read SEC document
May 02, 2024 Filed May 6, 2024 22:04 UTC	NeueHealth, Inc. NEUE · Entity 74308	GrantRestricted Stock Units · Derivative	580,000	$0.00	$0.00	Disclosure SEC source: 0001628280-24-020775 · wk-form4_1715033080.xml · derivative · entry 1 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 580,000 Underlying: Common Stock · 580,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: This grant was approved on October 11, 2023 by the Issuer's Compensation and Human Capital Committee, subject to shareholder approval of an amendment to the Issuer's Amended and Restated 2021 Omnibus Incentive Plan, which approval was obtained on May 2, 2024. F3 · derivative.exercise_date: 100% of these restricted stock units vest on October 11, 2026. F3 · derivative.expiration_date: 100% of these restricted stock units vest on October 11, 2026. Read SEC document
March 18, 2024 Filed Mar 21, 2024 00:01 UTC	NeueHealth, Inc. NEUE · Entity 74308	SaleCommon Stock	4,990	$7.27	$36,277.30	Disclosure SEC source: 0001628280-24-012336 · wk-form4_1710979263.xml · nonDerivative · entry 1 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,832 F1 · shares: These shares were sold by the reporting person to cover tax withholding obligations upon the vesting of restricted stock units and were not discretionary transactions by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.16 to $7.39 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
March 15, 2024 Filed Mar 19, 2024 00:14 UTC	NeueHealth, Inc. NEUE · Entity 74308	SaleCommon Stock	3,442	$7.10	$24,438.20	Disclosure SEC source: 0001628280-24-011759 · wk-form4_1710807289.xml · nonDerivative · entry 2 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,822 F1 · shares: These shares were sold by the reporting person to cover tax withholding obligations upon the vesting of restricted stock units and were not discretionary transactions by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.98 and $7.40 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
March 14, 2024 Filed Mar 19, 2024 00:14 UTC	NeueHealth, Inc. NEUE · Entity 74308	SaleCommon Stock	2,398	$7.06	$16,929.88	Disclosure SEC source: 0001628280-24-011759 · wk-form4_1710807289.xml · nonDerivative · entry 1 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,264 F1 · shares: These shares were sold by the reporting person to cover tax withholding obligations upon the vesting of restricted stock units and were not discretionary transactions by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.76 and $7.45 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
March 13, 2024 Filed Mar 14, 2024 01:21 UTC	NeueHealth, Inc. NEUE · Entity 74308	SaleCommon Stock	3,463	$7.30	$25,279.90	Disclosure SEC source: 0001628280-24-011050 · wk-form4_1710379289.xml · nonDerivative · entry 3 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,662 F1 · shares: These shares were sold by the reporting person to cover tax withholding obligations upon the vesting of restricted stock units and were not discretionary transactions by the reporting person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.11 and $7.52 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
March 12, 2024 Filed Mar 14, 2024 01:21 UTC	NeueHealth, Inc. NEUE · Entity 74308	SaleCommon Stock	1,598	$7.76	$12,400.48	Disclosure SEC source: 0001628280-24-011050 · wk-form4_1710379289.xml · nonDerivative · entry 2 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,125 F1 · shares: These shares were sold by the reporting person to cover tax withholding obligations upon the vesting of restricted stock units and were not discretionary transactions by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.40 and $8.10 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
March 11, 2024 Filed Mar 14, 2024 01:21 UTC	NeueHealth, Inc. NEUE · Entity 74308	SaleCommon Stock	2,664	$8.11	$21,605.04	Disclosure SEC source: 0001628280-24-011050 · wk-form4_1710379289.xml · nonDerivative · entry 1 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,723 F1 · shares: These shares were sold by the reporting person to cover tax withholding obligations upon the vesting of restricted stock units and were not discretionary transactions by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.85 and $8.38 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
March 08, 2024 Filed Mar 12, 2024 01:22 UTC	NeueHealth, Inc. NEUE · Entity 74308	SaleCommon Stock	5,096	$8.42	$42,908.32	Disclosure SEC source: 0001628280-24-010352 · wk-form4_1710206563.xml · nonDerivative · entry 3 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,387 F2 · shares: These shares were sold by the reporting person to cover tax withholding obligations upon the vesting of restricted stock units and were not discretionary transactions by the reporting person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.00 to $9.30 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
March 07, 2024 Filed Mar 12, 2024 01:22 UTC	NeueHealth, Inc. NEUE · Entity 74308	Exercise / conversionRestricted Stock Units · Derivative	7,565	$0.00	$0.00	Disclosure SEC source: 0001628280-24-010352 · wk-form4_1710206563.xml · derivative · entry 4 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,565 Underlying: Common Stock · 7,565 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: These restricted stock units vest in three equal annual installments beginning on March 7, 2023. F5 · derivative.expiration_date: These restricted stock units vest in three equal annual installments beginning on March 7, 2023. Read SEC document
March 07, 2024 Filed Mar 12, 2024 01:22 UTC	NeueHealth, Inc. NEUE · Entity 74308	SaleCommon Stock	7,886	$9.88	$77,913.68	Disclosure SEC source: 0001628280-24-010352 · wk-form4_1710206563.xml · nonDerivative · entry 2 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,483 F2 · shares: These shares were sold by the reporting person to cover tax withholding obligations upon the vesting of restricted stock units and were not discretionary transactions by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.32 to $11.05 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
March 07, 2024 Filed Mar 12, 2024 01:22 UTC	NeueHealth, Inc. NEUE · Entity 74308	Exercise / conversionCommon Stock	7,565	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-24-010352 · wk-form4_1710206563.xml · nonDerivative · entry 1 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,369 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
March 06, 2024 Filed Mar 8, 2024 23:38 UTC	NeueHealth, Inc. NEUE · Entity 74308	Exercise / conversionRestricted Stock Units · Derivative	58,877	$0.00	$0.00	Disclosure SEC source: 0001628280-24-010072 · wk-form4_1709941120.xml · derivative · entry 2 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,753 Underlying: Common Stock · 58,877 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: These restricted stock units vest in three equal annual installments beginning on March 6, 2024. F2 · derivative.expiration_date: These restricted stock units vest in three equal annual installments beginning on March 6, 2024. Read SEC document
March 06, 2024 Filed Mar 8, 2024 23:38 UTC	NeueHealth, Inc. NEUE · Entity 74308	Exercise / conversionCommon Stock	58,877	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-24-010072 · wk-form4_1709941120.xml · nonDerivative · entry 1 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,804 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
January 02, 2024 Filed Jan 4, 2024 21:21 UTC	AUTONATION, INC. AN · Entity 3730	GrantCommon Stock, par value $0.01 per share	1,659	$0.00	$0.00	Disclosure SEC source: 0000350698-24-000014 · wk-form4_1704403245.xml · nonDerivative · entry 1 Mikan George Lawrence III · CIK 0001381037 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,463 F1 · kind: 2024 grant of 1,659 vested restricted stock units (the "RSUs") pursuant to the AutoNation, Inc. 2014 Non-Employee Director Equity Plan (as amended, the "2014 Director Plan"). The RSUs will settle in shares of common stock, par value $0.01 per share, of AutoNation, Inc. (the "Company") in accordance with the terms of the award, including any deferral election made by the reporting person, and the 2014 Director Plan. Settlement of the RSUs will be accelerated in certain circumstances as provided in the terms of the award and the 2014 Director Plan, including in the event the reporting person ceases to serve as a non-employee director of the Company. Read SEC document
December 15, 2023 Filed Dec 19, 2023 02:14 UTC	NeueHealth, Inc. BHG · Entity 74308	SaleCommon Stock	25,202	$6.14	$154,740.28	Disclosure SEC source: 0001628280-23-041857 · wk-form4_1702952060.xml · nonDerivative · entry 2 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,927 F2 · shares: These shares were sold by the reporting person to cover tax withholding obligations upon the vesting of restricted stock units and were not discretionary transactions by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.70 to $6.68 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
December 14, 2023 Filed Dec 19, 2023 02:14 UTC	NeueHealth, Inc. BHG · Entity 74308	Exercise / conversionRestricted Stock Units · Derivative	52,500	$0.00	$0.00	Disclosure SEC source: 0001628280-23-041857 · wk-form4_1702952060.xml · derivative · entry 3 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 52,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: 60% of these restricted stock units vested on the 2nd anniversary of the grant date and 40% vest on the 3rd anniversary of the grant date. F4 · derivative.expiration_date: 60% of these restricted stock units vested on the 2nd anniversary of the grant date and 40% vest on the 3rd anniversary of the grant date. Read SEC document
December 14, 2023 Filed Dec 19, 2023 02:14 UTC	NeueHealth, Inc. BHG · Entity 74308	Exercise / conversionCommon Stock	52,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-23-041857 · wk-form4_1702952060.xml · nonDerivative · entry 1 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,129 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
August 21, 2023 Filed Aug 23, 2023 20:06 UTC	AUTONATION, INC. AN · Entity 3730	SaleCommon Stock, par value $0.01 per share	2,798	$160.03	$447,763.94	Disclosure SEC source: 0000350698-23-000116 · wk-form4_1692821194.xml · nonDerivative · entry 2 Mikan George Lawrence III · CIK 0001381037 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,804 F2 · price: This transaction was executed in multiple trades at prices ranging from $160.025 to $160.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document
August 21, 2023 Filed Aug 23, 2023 20:06 UTC	AUTONATION, INC. AN · Entity 3730	SaleCommon Stock, par value $0.01 per share	13,973	$159.50	$2,228,693.50	Disclosure SEC source: 0000350698-23-000116 · wk-form4_1692821194.xml · nonDerivative · entry 1 Mikan George Lawrence III · CIK 0001381037 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,602 F1 · price: This transaction was executed in multiple trades at prices ranging from $159.00 to $159.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document
May 04, 2023 Filed May 8, 2023 23:58 UTC	NeueHealth, Inc. BHG · Entity 74308	GrantRestricted Stock Units · Derivative	14,130,434	$0.00	$0.00	Disclosure SEC source: 0001628280-23-016581 · wf-form4_168359028141836.xml · derivative · entry 1 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,130,434 Underlying: Common Stock · 14,130,434 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: This grant was approved on February 24, 2023 by the Issuer's Compensation and Human Capital Committee as part of the Issuer's annual equity grants, subject to shareholder approval of an amendment to the Issuer's 2021 Omnibus Incentive Plan, which was obtained on May 4, 2023. F3 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on March 6, 2024. F3 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on March 6, 2024. Read SEC document
March 13, 2023 Filed Mar 16, 2023 00:46 UTC	NeueHealth, Inc. BHG · Entity 74308	SaleCommon Stock	394,896	$0.40	$157,958.40	Disclosure SEC source: 0001628280-23-008169 · wf-form4_167892758750186.xml · nonDerivative · entry 1 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,318 F1 · shares: These shares were sold by the reporting person to cover tax withholding obligations upon the vesting of restricted stock units and were not discretionary transactions by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.38 to $0.41 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
March 07, 2023 Filed Mar 10, 2023 01:27 UTC	NeueHealth, Inc. BHG · Entity 74308	Exercise / conversionRestricted Stock Units · Derivative	605,214	$0.00	$0.00	Disclosure SEC source: 0001628280-23-007409 · wf-form4_167841165323630.xml · derivative · entry 2 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,210,428 Underlying: Common Stock · 605,214 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on March 7, 2023. F2 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on March 7, 2023. Read SEC document
March 07, 2023 Filed Mar 10, 2023 01:27 UTC	NeueHealth, Inc. BHG · Entity 74308	Exercise / conversionCommon Stock	605,214	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-23-007409 · wf-form4_167841165323630.xml · nonDerivative · entry 1 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 605,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
January 03, 2023 Filed Jan 5, 2023 21:30 UTC	AUTONATION, INC. AN · Entity 3730	GrantCommon Stock, par value $0.01 per share	2,331	$0.00	$0.00	Disclosure SEC source: 0000350698-23-000014 · wf-form4_167295416663839.xml · nonDerivative · entry 1 Mikan George Lawrence III · CIK 0001381037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,575 F1 · kind: 2023 grant of 2,331 vested restricted stock units (the "RSUs") pursuant to the AutoNation, Inc. 2014 Non-Employee Director Equity Plan (as amended, the "2014 Director Plan"). The RSUs will settle in shares of common stock, par value $0.01 per share, of AutoNation, Inc. (the "Company") in accordance with the terms of the award, including any deferral election made by the reporting person, and the 2014 Director Plan. Settlement of the RSUs will be accelerated in certain circumstances as provided in the terms of the award and the 2014 Director Plan, including in the event the reporting person ceases to serve as a non-employee director of the Company. Read SEC document
January 03, 2023 Filed Jan 5, 2023 23:47 UTC	NeueHealth, Inc. BHG · Entity 74308	GrantRestricted Stock Units · Derivative	7,624,696	$0.00	$0.00	Disclosure SEC source: 0001628280-23-000536 · wf-form4_167296245738913.xml · derivative · entry 1 Mikan George Lawrence III · CIK 0001381037 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,624,696 Underlying: Common Stock · 7,624,696 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: All restricted stock units vest on the second anniversary of the grant date. F2 · derivative.expiration_date: All restricted stock units vest on the second anniversary of the grant date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.